Taken together, these studies suggest that combining CDK4/6is with direct CDK2 inhibition (instead of relying on MDM2 antagonists to increase p53 and p21 levels) could further enhance CDK4/6i therapeutic efficacy by potentially overcoming CDK4/6i resistance mechanisms in melanoma treatment. The gene discussed is CDK2; the disease is melanoma.